Clinical Trial
NCT03746522 Completed
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-BiedlSyndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity.
Disease
Disease type
Alström Syndrome
Bardet-Biedl
Hereditary retinal disease
Paediatric clinical trials
Retinitis Pigmentosa
Orphan drug recognition
NA
Patient type
Adult
Children
Inclusion / Exclusion
Funding
industry
Members involved
Main investigators
Pr Hélène Dollfus
Representative
France
Anterior Segment Rare Eye Diseases (WG4), CPMS & Digital Medecine (TWG10), Epag, ERN-EYE Coordinating committee, Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
ERN EYE member investigating site
HCP : Principal investigators
CARGO, Hôpitaux Universitaires de Strasbourg, France
Adress
Hôpital Civil -Bâtiment du Centre de Recherche en Biomédecine de Strasbourg (CRBS),1 Rue Eugène Boeckel
67000 STRASBOURG
France